Haemorrhagic and thrombotic disorders are common in myeloproliferative disorders (MPD) (Wasserman and Gilbert, 1966) in which a wide spectrum of platelet function has been described. Accelerated in-vitro aggregation has been reported during clinical thromboembolic episodes (Vreeken and Van Aken, 1971; Preston et al., 1974) , and platelet inhibition with aspirin is therapeutically useful in these cases.
Impaired in-vitro aggregation is more frequent (Berger et al., 1973) , but this pattern is paradoxically associated with thrombosis as well as bleeding. Since the platelet hypofunction appears not to protect against thrombosis, we should like to propose a new concept of the pathogenesis of platelet dysfunction in myeloproliferative disease.
Case report
A 70-year-old man was admitted to hospital with an acute exacerbation of chronic bronchitis. He gave a history of angina pectoris and intermittent claudication, and a recent episode of transient, left-sided hemiparesis. Physical examination revealed features of chronic obstructive lung disease but no residual central nervous system deficit. The spleen was palpable and he was normotensive.
Laboratory studies showed Hb 1 8-0 g/dl, haematocrit 58 6%, and WBC count 17 7 x 109/l (89% polymorphonuclear leucocytes with a left shift but no blasts). RBCs showed normochromia, anisopoikilocytosis, and some tear-drop forms, and the platelet count was 865 x 109/l with increased megathrombocytes. The leucocyte alkaline phosReceived for publication 26 July 1976 phatase score was 307, the ESR was 1 mm/hour, and bone marrow showed panhyperplasia of all cell series. Renal function tests were normal, uric acid was 10 mg/dl, and arterial blood gases showed PaO2 68 mmHg, PaCO2 33 mmHg, pH 7-45, S02 94%, and HCO3' 21 mEq/l (21 mmol/l). The red cell mass and plasma volume were not measured.
Platelet aggregation studies performed on admission, using standard techniques (Ginsburg, 1975) , showed marked unresponsiveness to adenosine diphosphate, collagen, and adrenaline ( Fig. 1) .
On a regimen of penicillin, cloxacillin, theophylline, corticosteroids, and oxygen, blood gases became normal, but on the second day he developed a right-sided hemiparesis with cerebrospinal fluid evidence of subarachnoid haemorrhage. The platelet count fell to 420 x 109/1 and remained at this level until death. Disseminated intravascular coagulation was suspected, but coagulation screening tests were normal, fibrinogen was 3 0 g/l, and fibrin degradation products were not raised.
On the tenth day he developed positive faecal occult blood and widespread skin petechiae. A phlebotomy of 450 ml was performed, but on the twelfth day he sustained a myocardial infarction and died of a cardiac arrest the next day.
NECROPSY FINDINGS
Atherosclerosis was present in the aortic, coronary, renal, and cerebral arteries. Many aortic plaques were covered by fresh polypoid thrombi (Fig. 2) consisting of granular platelet material and fibrin (Fig. 3) . PTAH staining confirmed the large numbers of platelets in these lesions (Fig. 4) (Berger et al., 1973) and cannot be ex-CONTROLOROL plained by the drugs used in his management (Mustard et al., 1972; Cazanave et al., 1973 (Weinfeld et al., 1975) and were elevated in this patient. Though Fig. 1 PATIENT PATIENT
shows the majority of patient's platelets to be functionally impaired, a small number do appear to 2 2 , | be sensitive to the various reagents used. It is, 2 3 1 2 3 4 therefore, likely that the platelet-rich thrombi seen at TIME (min) TIME (min) necropsy were generated from the circulating platelet population which had retained some normal COLLAGEN function. CONTROL Both impaired and accelerated platelet function is reported in myeloproliferative disease (vide supra), and aggregation patterns can change in individual patients. Phlebotomy may improve platelet aggre-PATINT gation in polycythaemia rubra vera (Berger et al., 1973), and we have observed this in 40% of our patients within three days of phlebotomy. Unlike chemotherapy, phlebotomy would not be expected 2 3 4 5 6 7 8 9 to reduce the production of abnormal platelets by TIME (min) malignant megakaryocytes, and another explanation t aggregation studies in thepatient anda is needed to explain these observations. Figure 8 summarises our proposals and is supported by much evidence in the literature.
Ultrastructural studies in myeloproliferative ,hiae. Many intramyocardial arteries disease have shown normal platelet granulation Ltelet-rich thrombi (Fig. 5) .
within the bone marrow (Lagerlof and Franzen, omboemboli were present in the cere-1972), in contrast to the marked degranulation of Lal arteries (Figs. 6 and 7) and in the peripheral blood platelets (Maldonado et al., 1974) . Is. Multiple haemorrhagic infarcts were The delivery of functionally normal platelets to the cerebral cortex, thalamus, cerebellum, bloodstream in response to phlebotomy is further spleen.
evidence that thrombopoiesis is probably normal in hiae were widespread, but no source of these disorders. al bleeding was found. Emphysematous Myeloproliferative patients are known to exseen in the lungs, but no pulmonary perience episodes of disseminated intravascular )resent. platelet aggregation (Vreeken and Van Aken, 1971; Preston et al., 1974) and circulating platelet aggregates have been shown in a number of clinical circumstances (Wu and Hoak, 1974) . The microof this case suggest the diagnosis of a vascular symptoms common to myeloproliferative ative disorder, despite the possibility disease are probably due to small vessel platelet hypoxic polycythaemia. The impaired aggregates, and in our experience they respond dramatically to aspirin. Large-vessel thromboemboli are also common and, as in this patient, platelets are involved in this process too. A recent review (Mustard, 1975) emphasises that platelet aggregates tend to break up in their passage through the microcirculation. Platelets can survive such events (Mustard et al., 1966) , and their lifespan in vivo may be unaltered by as many as three episodes of thrombin-induced aggregation and disaggregation (Reimers et al., 1973) . Platelet function, however, is compromised by agents which trigger the platelet release reaction, and the aggregation patterns produced by pre-exposure to thrombin or shearstress forces (Reimers et al., 1973; Harbury and Schrier, 1974; Brown et al., 1975) are very similar to the ones seen in myeloproliferative disease. Since the myeloproliferative defect is acquired in the peripheral blood, it is probably due to damage sustained during DIPA. The overall pattern of in-vivo aggregation would, therefore, depend on a balance between the marrow release of normal platelets and their subsequent injury in the circulation.
A predominantly damaged population of platelets would exacerbate bleeding from sites of infarction or produce a generalised bleeding diathesis. It (Vreeken and Van Aken, 1971; Preston et al., 1974) . In these circumstances, chemotherapeutic marrow suppression or inhibition of platelet function with aspirin can produce remission of symptoms (Preston etal., 1974) .
Several factors are likely to precipitate DIPA. Atherosclerotic arterial disease is common to these patients, and thromboembolus formation at proximal sites of atheroma is well documented in polycythaemia rubra vera (Barabas et al., 1973) . Arterial disease is probably important in localising the site of symptoms in individual patients. Thrombocythaemia and polycythaemia are also factors which may precipitate DIPA since their correction may also improve platelet function (Berger et al., 1973; Zucker and Mielke, 1972; Spaet et al., 1969) . Lastly, since platelet function is normal in patients with secondary thrombocytosis (Ginsburg, 1975) , there may be intrinsic features of the myeloproliferative platelet which tend to produce DIPA.
The above speculations explain many of the conflicting reports on platelet function in myeloproliferative disease and have important implications concerning the use of platelet inhibitors, such as aspirin, in these disorders.
